Caplin Point laboratories

Caplin Point laboratories operates through Caplin Point Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.

2 investors in total: 2 institutional.

Caplin Point laboratories has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eight Roads Ventures and F-Prime Capital.

All

Venture Fund

Investor	Description	Founded Year	Domain	Location
Eight Roads Ventures	Venture capital investment and global platform support for startups.	2008	eightroads.com	London, United Kingdom
F-Prime Capital	Investments in life sciences, technology, healthtech, and crypto sectors from global locations.	–	fprimecapital.com	-

Premium access

Investor details for Caplin Point laboratories

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

• Complete investor list
• Round participation
• Investor portfolios
• Co-investor network

Access investors

Verified entity values are shown only after access is granted.

Caplin Point Laboratories Limited is the primary company behind Caplin Point laboratories. The board of Caplin Point Laboratories Limited currently have 9 directors; the longest-serving is Paarthipan Chingelput Chellappan, appointed in 1993. 22 earlier directors have ceased.

33 people are tracked at Caplin Point laboratories (8 in leadership, 5 in board & advisors, 20 in team); the tracked headcount is 5,530.

13 more people are available in the full profile.

Figures of Caplin Point Laboratories Limited, the primary company behind Caplin Point laboratories, for FY 2025. Revenue was ₹2,034 Cr (+15% year on year). Net profit was ₹541 Cr (27% margin). EBITDA was ₹743 Cr (37% margin). Revenue has grown at a compounded annual rate of +16% over three years and +18% over five years.

• ₹2,034 CrRevenue · FY 2025 · +15% YoY
• ₹541 CrNet profit · 27% margin
• ₹743 CrEBITDA · 37% margin
• ₹15.20 CrPaid-up capital
• 987Employees (provident fund records)
• +16%Revenue CAGR, 3 years
• +18%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Caplin Point Laboratories Limited are on its company page.

3 dated milestones of Caplin Point laboratories across 29 years, from founding to its latest funding, stage changes and deals.

1. 1990 Founded Caplin Point laboratories is founded.
2. Jun 2014 IPO Lists on the stock exchange (IPO).
3. Jan 2019 Funding First funding round of $30.6M.

The website of Caplin Point laboratories (caplinpoint.net) receives about 24.4K visits a month and ranks #1,150,705 among all websites worldwide, #10,053 in Investing.

• Monthly visits
  24.4K

  ▲ 6.3% vs previous month

• Unique visitors
  8.8K

  per month

• Global rank
  #1,150,705

  among all websites

• Category rank
  #10,053

  Finance · Investing

Websites whose visitors overlap most with Caplin Point laboratories. Affinity shows how closely the audiences match.

Website	Domain	Audience affinity	Monthly visits	Global rank	Profile
BSE India	bseindia.com	100%	10.6M	–	View details
screener.in	screener.in	100%	–	#1,968	–
saprlaw.com	saprlaw.com	80%	–	#6,314,156	–

10 companies that operate in the same segment as Caplin Point laboratories (Traditional Health & Nutrition), ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Amneal	Manufacturer of generics formulations	2002	Bridgewater, New Jersey, United States	–	USD 3.02 B	8,300
Coherus Biosciences	Biosimilar therapeutics are developed for oncology and autoimmune diseases.	2010	Redwood City, California, United States	USD 143.62 M	USD 42.17 M	228
Inventia Healthcare	Oral solid drug delivery systems are manufactured and developed.	1985	Mumbai, Maharashtra, India	USD 42.49 M	USD 89.42 M	962
Bausch & Lomb	Ophthalmic pharmaceuticals and instruments are developed for eye care.	1853	Bridgewater, New Jersey, United States	–	USD 5.1 B	13,500
Teva Pharmaceuticals	Generic pharmaceuticals are manufactured by Teva Pharmaceuticals.	1901	Petah Tikva, Central District, Israel	USD 500 M	USD 18.74 B	51,792
Strides Pharma Science	Generic, semi-solid, and liquid dosage forms are manufactured.	1990	Bengaluru, Karnataka, India	–	USD 508.93 M	5,180
Alvogen	Pharmaceutical products are developed and marketed globally.	2009	Montville, New Jersey, United States	USD 155.92 M	–	–
Sun Pharma	Specialty generic pharmaceuticals and APIs are manufactured and marketed.	1983	Mumbai, Maharashtra, India	–	USD 6.21 B	25,870
Mankind Pharma	Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations	1991	Delhi, Delhi, India	USD 367.2 M	USD 1.52 B	21,320
Wockhardt	Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt.	1967	Mumbai, Maharashtra, India	–	USD 353.53 M	3,410